Lipid Metabolism Alteration by Endocrine Disruptors in Animal Models: An Overview
1Dipartimento Scienze della Vita e dell'Ambiente, Università Politecnica delle Marche, Ancona, Italy
2INBB Consorzio Interuniversitario di Biosistemi e Biostrutture, Rome, Italy
*Correspondence: Francesca Maradonna f.maradonna@univpm.itOliana Carnevali o.carnevali@univpm.itAbstract
Exposure to potential Endocrine Disrupting Chemicals (EDCs) pose a documented risk to both wildlife and human health. Many studies so far described declining sperm counts, genital malformations, early puberty onset, highlighting the negative impact on reproduction caused by the exposure to many anthropogenic chemicals. In the last years, increasing evidence suggested that these compounds, other than altering reproduction, affect metabolism and induce the onset of obesity and metabolic disorders. According to the “environmental obesogens” hypothesis, evidence exists that exposure to potential EDCs during critical periods when adipocytes are differentiating, and organs are developing, can induce diseases that manifest later in the life. This review summarizes the effects occurring at the hepatic level in different animal models, describing morphological alterations and changes of molecular pathways elicited by the toxicant exposure. Results currently available demonstrated that these chemicals impair normal metabolic processes via interaction with members of the nuclear receptor superfamily, including steroid hormone receptors, thyroid hormone receptors, retinoid X receptors, peroxisome proliferator–activated receptors, liver X receptors, and farnesoid X receptors. In addition, novel results revealed that EDC exposure can either affect circadian rhythms as well as up-regulate the expression of signals belonging to the endocannabinoid system, in both cases leading to a remarkable increase of lipid accumulation. These results warrant further research and increase the interest toward the identification of new mechanisms for EDC metabolic alterations. The last part of this review article condenses recent evidences on the ability of potential EDCs to cause “transgenerational effects” by a single prenatal or early life exposure. On this regard, there is compelling evidence that epigenetic modifications link developmental environmental insults to adult disease susceptibility. This review will contribute to summarize the mechanisms underlying the insurgence of EDC-induced metabolic alterations as well as to build integrated strategies for their better management. In fact, despite the large number of results obtained so far, there is still a great demand for the development of frameworks that can integrate mechanistic and toxicological/epidemiological observations. This would increase legal and governmental institution awareness on this critical environmental issue responsible for negative consequences in both wild species and human health.
Introduction
The first definition of Endocrine disrupting chemicals (EDCs) was provided at the European Workshop on endocrine disruptors (EDs) hold in Weybridge UK, in 1996. “An endocrine disruptor is an exogenous substance that causes adverse health effects in an intact organism, or its progeny, secondary to changes in endocrine function.” A further definition was also agreed, concerning potential EDs: “A potential endocrine disruptor is a substance that possesses properties that might be expected to lead to endocrine disruption in an intact organism.”
EDCs, interfering with the endocrine (or hormonal) system, are tightly implicated in the global decline of metabolic health. This large and multifaceted family includes plasticizers as phthalates, bisphenols, industrial chemicals including alkylphenols, flame retardants, air pollutants, such as polycyclic aromatic hydrocarbons, pesticides, metals, and dioxins. Consumption of contaminated food and water and inhalation of airborne pollutants represent the major sources of human exposure to EDCs, significantly contributing to the onset of obesity (1) by inappropriately stimulating adipogenesis as well as perturbing lipid metabolism and energy balance (2). All those EDCs that inappropriately regulate and promote lipid accumulation and adipogenesis are defined “obesogens” (3). In the last years, with the addition of compounds able to affect lipid metabolism, the list of obesogenic compounds significantly enlarged. Exposure to EDCs, in fact, can directly increase the size/number of adipocytes or indirectly affect basal metabolic rate and hormonal control of appetite (4). The hypothalamic-pituitary-adrenal axis plays an important role in controlling appetite and satiety, stimuli regulated by a variety of monoaminoergic, peptidergic and endocannabinoid (EC) signals that can be generated in the digestive tract, adipose tissue and brain. All these signals are candidate targets of potential obesogenic EDCs. Lipids, which role has been considered crucial in many tissues including liver, fat and intestine are accumulated and stored till their use in case of energy needs (5). Many studies so far have been carried out to reveal the pivotal role of dietary lipid intake as a source of essential fatty acids governing energy balance, food intake, growth, reproduction and health. Dysregulation of lipid accumulation is at the basis of several metabolic syndromes, including Nonalcoholic Fatty Liver Disease (NAFLD) and hyperlipidemia (6). The windows of exposure to potential EDCs (e.g., fetal or early postnatal) is critical for the outcome of metabolic diseases and results particularly detrimental because of the permanent effects on obesity later in life.
Since the socio-economic burden of EDC-caused diseases in industrialized countries ranges between 50 and 300 billion €/year (7), research to increase the knowledge on the causal link between health effects and EDCs represents a great challenge for health care systems.
This review is aimed at providing a general overview on the endocrine mechanisms linking EDC exposure to lipid metabolism dysregulation in different experimental vertebrate models, from mammals to fish, also considering in vitro trials.
Potential mechanisms by which EDCs exert their effects
To better understand how potential EDCs can dysregulate lipid metabolism leading to the onset of several health diseases, a brief overview of the mechanisms and of the main actors involved in the regulation of lipid synthesis and degradation will be given.
In the last decades, the study of a group of xenobiotic compounds known as peroxisome proliferators has led to the discovery of peroxisome proliferator-activated receptors (PPARs) as a novel subfamily of nuclear receptors (NRs) (8). They dimerize with retinoid X receptor (RXR) and bind to PPAR-responsive DNA regulatory elements controlling the expression of genes involved in adipogenesis, glucose, lipid, and cholesterol metabolism (9, 10). Similarly to the membrane Estrogen receptorα (ERα), recently it has been demonstrated that PPARs can activate a non-genomic, rapid signaling pathway (11, 12), but while several studies so far described the activation of the ER non-genomic, rapid pathway in response to potential EDCs (13–16), information regarding ability of pollutants to activate the PPAR-non genomic signaling is still lacking.
PPARs have a pivotal role in regulating metabolism, resulting the primary lipid sensors in vertebrates and being highly conserved between humans and zebrafish (17). Poly and mono unsaturated fatty acids (FA), eicosanoids and lipophilic hormones are PPAR natural ligands (18) with different affinity to PPAR isoforms and induce the expression of genes and enzymes involved in lipid metabolism. In addition to natural ligands, phthalates, plasticizers, certain herbicides, biocides organotins, perfluorooctanoic (PFOA) and perfluorooctanesulfonic (PFOS) acids, pharmaceuticals, halogenated derivatives of bisphenol A (BPA), the imidazole fungicide triflumizole, the fibrate class of hypolipidemic drugs, all listed as “Endocrine Disruptive Chemicals,” interact with the above stated NR through a specific binding mechanism (19). The activation of RXR- PPARα dimer stimulates FA β-oxidation (20), while the RXR-PPARɤ heterodimer favors preadipocytes differentiation and regulates lipid biosynthesis and storage (21) (Figure 1). In most species, the major site of both lipolytic and lipogenic processes is the liver, where PPARα and β, other than regulating FA β-oxidation, have a key role in glucose storage, lipoprotein capture and inflammation reduction (22), while the activation of PPARɤ orchestrates adipocyte function and differentiation as well as lipid storage within adipocytes (9). In the liver, PPARα is abundantly expressed, whereas PPARβ and PPARɤ are expressed at lower levels. PPARα, being the major regulator of the hepatic response to fasting, induces the expression of a variety of genes involved in FA catabolism and ketogenesis (23). Consequently, fasting PPARβ knockout mice develop hepatic steatosis (23). In addition to PPARɤ, several genes regulate fat cell development and control, including CCAAT-enhancer-binding proteins (c/ebp), responsible for the secretion of adipokines, e.g., leptin and adiponectin, hepatic glucose metabolism, insulin sensitivity and inflammation (24). A side from PPARs and C/EBP, sterol regulatory element-binding proteins (SREBPs) are central players in lipid metabolism, controlling the expression of genes important for lipid synthesis and uptake (25). In addition to the canonical functions in the transcriptional regulation of genes involved in lipid biosynthesis and uptake, SREBPs are also implicated in pathogenic processes including, inflammation, autophagy and apoptosis, and in this way, they contribute to the onset of several metabolic disorders (26). Activation of selected pathways responsible for adipogenesis and lipogenesis are summarized in Figure 2.
Once synthesized, lipids are stored within hepatocytes as source of energy. At the same time in these cells xenobiotic detoxification takes place. P450 enzymes are mainly implicated in this process via ligand-activated xenobiotic receptors, mainly aryl hydrocarbon receptor (AHR), constitutive androstane receptors (CAR) and pregnane X receptor (PXR). Recently, it was proposed that activation of these xenobiotic receptors is a triggering event of hepatic steatosis (30). To increase the knowledge regarding this aspect, it should be briefly considered the role of some signals involved in lipid regulation. In most species, triacylglycerol (TAG) is the main dietary component and lipoprotein lipase (LPL) is deputed to its hydrolyzation into non-esterified FA and 2-monoacylglycerol and their further storage in lipid droplets. It acts as “gate keeper” of FA uptake, working as a rate limiting enzyme in the provision of fatty acids to tissues (31). Intracellular transport of FA is performed by fatty acid binding proteins (FABP), which sequesters lipophilic compounds, regulates hepatocyte growth and transport them into mitochondria (32). Once stored in mitochondria, a set of genes involved in different aspects of lipid metabolism are activated (33). Fatty acid synthase (FAS) catalyzes the main pathway of lipogenesis, producing long saturated chain of carbon's atoms, finally stored in adipose tissues (34). Considering this brief state of art, it's clear that pivotal in this context is the ability of potential EDCs to interfere with/activate the PPAR cascade.
As novelty, recently, evidence emerged showing that one potential mechanism by which chemical exposure can influence lipid metabolism is through disturbance of circadian rhythms. While the circadian signals generated by clock genes produce metabolic rhythms, clock gene function is tightly coupled with fundamental metabolic processes, such as glucose and lipid metabolism (35). It has been demonstrated that the expression of clock genes, Dec1, Dec2, and Bmal1, is directly linked to energy metabolism, since ppar regulation is under the control of clock proteins. More specifically, DEC1 and DEC2 regulate adipogenesis by repressing the transcription of pparɤ (36).
In the last years, a direct link between the EC system and its role in the regulation of energy balance and in the onset of obesity emerged. ECs, differently from the protein hormone-based circuits and from the classical brain neurotransmitters, are synthesized and act locally and their effects are mediated by binding to surface receptors (37). Increasing evidence suggested that ECs bind and activate PPARs, being ECs fatty acids derivatives (38). It is likely that ECs, whose chemical structure is derived from arachidonic acid, might act not only through the classical type 1 and type 2 cannabinoid receptors (CB1 and CB2), the GPR55 orphan receptor and vanilloid type-1 receptor (VR1), but also through PPARs. Therefore, the binding between ECs and PPARs might mediate many of the biological effects of cannabinoids, including modulation of feeding behavior and lipid metabolism. Recent studies demonstrated the ability of potential EDCs to regulate the EC system. Among phthalates, the di-ethyl-hexyl-phthalate (DEHP) exerts its obesogenic action up-regulating hepatic pparα, cb1, and srebp levels and stimulating de novo FA synthesis and hepatic steatosis. This hepatic state may cause an inhibition of food intake stimulus up-regulating leptin, the typical sensor of the energy status, which, in the brain, may negatively control cb1 and in turn reduce srebp gene expression (25).
Transgenerational epigenetic inheritance: focus on the effects on adipogenesis and lipid metabolism signals
Recent studies revealed that the increasing incidence of obesity, in addition to being due to bad life styles and occupational stress, could be also caused by exposure to xenobiotics and transmitted to subsequent/following generations on an epigenetic inheritance base (77). To be called transgenerational, expression of the trait has to persist for at least two or three generations (three mammals, two fish) after the initial exposure to the environmental agent (78, 79). This section will describe the epigenetic mechanisms underlying developmental plasticity and uncovering the existence of a mechanistic link between altered epigenetic gene regulation following an early toxicant exposure and potential onset of obesity later in the life. In general terms, evidences demonstrated that the obesogenic effects of potential EDCs are mediated by their ability to bind NRs. These receptors directly recruit methyl and acetyltransferase, thus altering epigenetic marks regulating gene expression (80). In this way, EDCs can modify chromatin states or the levels of DNA or histone methyltransferases (81). As stated above, one of the main target of obesogens is PPARɤ, the master regulator of adipogenesis or its target-related genes. During the first developmental stages, PPARɤ regulates the differentiation of MSCs into osteocytes or adipocytes. An in vitro exposure of 3T3-L1 preadipocytes cell line to TBT, resulted in an increase of the number of differentiated adipocytes associated with a global decrease of DNA methylation (82). The same cell line exposed for 8-days to brominated diphenyl ether 47 (BDE-47), differentiated into adipocytes and presented higher levels of pparɤ2, cebpα, cebpβ, cebpɤ, srebf1a, lpl, Slc2a4, fabp4, Adipoq, G6pc, Lep, and Igf1. Variation of pparɤ2 expression was associated with a decreased methylation of 3 CpG sites in promoter region (83). Moving to in vivo studies, in adipose-derived stem cells (ADSCs) isolated from white adipose tissue of C57BL/6J mice perinatally exposed to TBT by maternal gavage, increased lipid accumulation in differentiated adipocytes associated with an increase of early adipogenesis markers, pparɤ and fapb4, were measured. In these genes, hypomethylation of promoter/enhancer region of fapb4 but not of pparɤ2 were observed (82). Prenatally exposure of BALB/cByj mice (F1) to mixture of PAHs, displayed increased adult adipocyte size. The size alteration was also observed in F2-offspring and were associated in both F1 and F2, to general increased pparɤ, cox2, and cebpα expression in adipose tissue. In both males and females of F1 and F2, a decreased methylation of 1 CpG site in pparɤ promoter was detected, inversely correlating with pparɤ expression (84). In a transgenerational study, outbred gestating female rats were transiently exposed to DDT and the F1 generation offspring bred to generate the F2 generation and F2 generation bred to generate the F3 generation. The F1 and F3 generation were aged and various pathologies investigated. The transgenerational transmission of disease was through both female (egg) and male (sperm) germlines. F3 generation sperm epimutations and differential DNA methylation regions of a number of obesity-related genes were induced by DDT. Interestingly, in this study, the authors concluded that male obesity is transmitted through the female germline and female obesity transmitted through the male germline (78). In a study using rats, females were daily intraperitoneally injected with methoxychlor from days 8 to 14 of gestation and then the onset of disease was evaluated in adult F1 and F3 generation progeny. Increase of obese rate was observed especially in the F3 and F4 generation demonstrating that female germline transmission of environmentally induced epigenetic transgenerational phenotypes is equally as stable as male germline transmission (85). In another study, gestating female rats were transiently exposed from days 8 to 14 of embryo gonadal sex determination to a plasticizer mixture containing BPA, DEHP and dibutylphthalate (DBP) and the incidence of adult onset disease was evaluated in F1 and F3 generation rats. Obesity significantly increased in F3 rats (86). Epidemiological evidence showed that the developmental programming can be transferred to subsequent generation. The exposure to NP during critical windows of development, including fetal and/or early postnatal periods, can induce permanent alterations in adipose tissue and then obesity in mouse (87). NP action is mediated by ERα signaling pathway and the receptor deletion causes abdominal fat accumulation due to increased number and size of fat cells, increased levels of cholesterol and leptin and alteration in the expression of genes involved in lipogenesis and adipogenesis, in the two generation offspring's (88). Similarly to NP, it is well-known that BPA induces epigenetic modification (89, 90) and exerts its obesogenic action by binding ERα. The hormone-like-receptor complex bind the estrogen responsive element in the promoter of histone modifying methyltransferase EZH2 gene. After binding, several co-regulators are attracted and the up-regulation of the EZH2 levels increase H3K27 trimethylation (91). Recently Helsley and Zhou (92), reviewed the central role of PXR in lipid homeostasis. These evidences clearly suggest that although the research on obesogens mainly focuses on PPARɤ as master regulator, the involvement of other receptors, including steroid hormone receptor and PXR should be evaluated.
Conclusion
In conclusion, this review summarizing the most recent results describing the effects of potential EDC administration on metabolic health, clearly evidences the risk caused by the exposure to environmental chemicals (Table 1). A summary of the most common lipid metabolism alterations following their exposure has been presented. In addition, novel data regarding their ability to affect circadian rhythms as well as to up-regulate the expression of the ECS, in both cases leading to a remarkable increase of lipid accumulation, have been also reported. Finally, evidences of their“transgenerational obesogenic effects” following a prenatal or early life contamination have been discussed.
| Environmental pollutant | Animal model | Biological effect observed | Bibliography |
|---|---|---|---|
| Benzophenone 3 (BP-3) | Zebrafish, Danio rerio | Obesity induction and alteration of circadian rhythms | (57) |
| Bisphenol A (BPA) | 3T3-L1 pre-adipocytes | Adipocyte metabolic dysfunction and inflammation | (53) |
| Zebrafish | Induction of TAG accumulation by up-regulation of ECS | (64) | |
| HHL-5 cells | Induction of TAG accumulation by up-regulation of ECS | (64) | |
| Zebrafish | Increased presence of hepatic lipid vacuoles, caused by alteration of the ECS | (61) | |
| Increased TAG storage and FA synthesis, de novo lipogenesis and cholesterologenesis promotion | (65) | ||
| Evidence of the miRNome involvement in lipid synthesis, oxidation and related diseases | (67) | ||
| Seabream, Sparus aurata | Hepatic lipid accumulation associated to a decrease of lipid mobilization | (70, 71) | |
| Alteration of hepatic structure lipids and TAG content and decreased phospholipids and glycogen abundance | (75) | ||
| Marine medaka, Oryzias javanicus | Upregulation of apo A-IV, apo A-I, Acsl1, Elovl, and fabp | (76) | |
| Brominated diphenyl ether 47 (BDE-47) | 3T3-L1 pre-adipocytes | Increased levels of Pparɤ2, Cebpα, Cebpβ, Cebpɤ, Srebf1a, Lpl, Slc2a4, Fabp4, Adipoq, G6pc, Lep, and Igf1. Transgenerational study | (83) |
| Cypermethrin (CYP), atrazine (ATZ), 17α-ethynyestradiol (EE2) | C57BL/6J mice | Alteration of the hepatic levels of PPARα, PPARɤ, and SREBP1C | (52) |
| Dibutyltin (DBT) | Human MSCs | C/EBPα, PPARγ2, FABP4, FSP27, LPL upregulation | (44) |
| Dichlorodiphenyltrichloroethane (DDT) | Hsd:Sprague Dawley®™SD®™ Harlan | Obesity induction in males. Transgenerational study | (78) |
| Di(2-ethylhexyl) phthalate (DEHP) | HepG2 cells | Activation of the SREBP-1c and PPARα-signaling pathway | (49) |
| Zebrafish | Alteration of FOXA2 and FOXA3 transcription factor networks', “Metabolic pathways,” “metabolism of amino acids and derivatives,” “metabolism of lipids and lipoproteins,” and “fatty acid, triacylglycerol, and ketone body metabolism” | (56) | |
| Up-regulation of hepatic PPARα, Cb1, and SREBP levels, de novo FA synthesis and hepatic steatosis | (63) | ||
| Sprague-Dawley rats | Hepatic steatosis, associated to inflammation, lipid peroxidation, oedema of the liver cells and hepatic damage | (48) | |
| Di-isodecyl- phthalate (DiDP) | Seabream | PPAR-mediated regulation of fabp | (74) |
| DiNP | Zebrafish | Upregulation of orexigenic and hepatosteatosis signals, deregulation of the peripheral and central ECS and lipid metabolism | (62) |
| DiNP | Seabream | Alteration of hepatic structure lipids and triglycerides content and decreased phospholipids and glycogen abundance | (75) |
| Diethylene glycol dibenzoate (DGB) | Zebrafish | Increase of de novo lipogenesis, cholesterol esters, TAG production and potential conversion of lipids into apolipoprotein particles | (65) |
| Seabream | PPARα agonist, stimulation of key lipolytic genes and downregulation of ECS | (73) | |
| Methoxychlor | Sprague-Dawley rats | Obesity induction in females. Transgenerational study | (85) |
| BPA, DEHP and dibutylphthalate (DBP) mixture | Sprague-Dawley rats | Obesity induction. Transgenerational study | (86) |
| Nonylphenol (NP) | Sprague-Dawley rats | Hepatic srebp-1C, fas and ucp2 upregulation | (46) |
| Wistar rats | Obesity induction, increased levels of cholesterol and leptin and alteration of the expression of genes involved in lipogenesis and adipogenesis. Transgenerational study | (87, 88) | |
| Seabream | Hepatosteatosis, alteration of lipid metabolism | (69, 71) | |
| BPA, NP, tert-octylphenol (t-OP) Mixture | Seabream | Alteration of lipid metabolism | (72) |
| Polycyclic aromatic hydrocarbon (PAH) mixture | BALB/cByj mice | Increased Pparɤ, Cox2, and Cebpα expression in adipose tissue. Transgenerational study | (84) |
| RXR-specific ligands LG100268 and AGN195203 | African clawed frog, Xenopus laevis | Ectopic adipocyte formation around the gonads | (43) |
| Tributyltin (TBT) | murine 3T3-L1 adipocytes | RXR-PPARɤ-mediated pro-adipogenesis in liver and adipose tissue | (40, 41, 42) |
| Increase the number of differentiated adipocites. Transgenerational study | (82) | ||
| C57BL/6 mice | Lipid accumulation in adipose tissues and onset of hepatic steatosis | (43) | |
| Increased lipid accumulation in differentiated adipocytes associated to an increase of early adipogenesis markers, Pparɤ and Fapb4. Transgenerational study | (82) | ||
| African clawed frog | Activation of RXR/PPARɤ pathways | (43) | |
| Zebrafish | Male: increased body weight, hepatosomatic index, hepatic TAG abundance and expression of adipogenesis and lipogenesis genes pparγ, srebp1, fasn, 11β-hsd2, c/ebpβ, and dgat2 Female: hepatomegaly with lack of response of signals involved in adipogenesis | (54) | |
| Obesity induction and alteration of circadian rhythms | (57) | ||
| Trout (Oncorhynchus mykiss) Primary adipocyte culture | Promotion of adipocytes differentiation by enhancing PPARγ and C/EBPα protein expression | (60) | |
| 2,3,7,8-Tetrachlorodibenzodioxin (TCDD) | C57BL/6J mice | Sex specific modulation of mRNA levels involved in adipose tissue and hepatic metabolism, inflammation, xenobiotic metabolism and endocrine disruption | (50) |
| AHR mediates obesity and fatty liver onset | (51) | ||
| Tetrabrominated bisphenol A (TBBPA) | Zebrafish | Obesity induction and alteration of circadian rhythms | (57) |
| t-OP | Seabream | Hepatosteatosis, alteration of lipid metabolism | (69, 71) |
| Triclosan (TCS) | Zebrafish | Upstream regulation of miR-125b | (68) |
| Human MSCs | decreasing aP2, lpl, and adipoq gene expression | (47) | |
| Zebrafish | impaired mRNA expression levels of β-oxidation transcripts and lipid β-oxidation genes, including pparα, cpt1, lpbe, cyp4a10, and aco | (55) | |
| Tyhriphenyltin (TPT) | Trout Primary adipocite culture | Promotion of adipocytes differentiation by enhancing PPARγ and C/EBPα protein expression | (60) |
| tris (1,3-dichloroisopropyl) phosphate (TDCIPP) | Zebrafish | Obesity induction and alteration of circadian rhythms | (57) |
The integration of results suggests that hepatic steatosis, the first signal of the onset of several metabolic diseases, easily occurs following the exposure to environmental concentrations of pollutants, thus triggering an increase of FA synthesis or uptake and their decreased oxidation. Widespread pollutants including BPA, phthalates, PFCs, POPs, and TBT, targeting NR, induce FA synthesis in different animal models, highlighting the activation of a common pathway mediating the toxicity among species. The main evidence consists in the fact that liver also mediates xenobiotic metabolism which may increase oxidative stress and in turn impacts the correct FA metabolism. However, since few evidence still exists to characterize pathways and patterns leading to altered functional development, all these results should be considered and integrated by Environmental Agencies to propose novel biomarkers and innovative endpoints for the development of novel Organization for Economic Co-operation and Development (OEDC) test guidelines to screen chemical danger for metabolic functions.
Acknowledgements
The authors wish to thank Dr. Danilo Basili for the English revision, Dr. Marco Graziano for kindly providing the seabream drawing (http://tiktaalikillustrations.com), and Dr. Elisabetta Giorgini for support with FTIR analyses.